Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Alveus Therapeutics raised $197 million in an oversubscribed Series A financing, co-led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, to advance its clinical pipeline.
PRIVATEJun 03, 2026•2 months ago
Amount Raised
$197 Million
Round Type
Series A
PhiladelphiaBiotechnologyHealth CareInvestors
Novo HoldingsJeito CapitalSanofi VenturesOmega FundsAndera PartnersNew Rhein Healthcare Investors
Description
Alveus Therapeutics officially entered the global spotlight with a Series A financing of up to $197 million in two tranches. The first tranche of $159.8 million was co-led by notable investors while the second tranche received support from Jeito Capital and Novo Holdings. This funding will be used for the clinical advancement of its core pipeline and IND application. Alveus is well-positioned in the competitive weight loss drug market.
Related People
Suggested for you
1 contactVerified contactsXiao-Ping P., Chief Technical Officer, Head of CMC an… hidden
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech